Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases-Reference-Cited by-同舟云学术

Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases

Published:2022-06 Issue:6 Volume:10 Page:1515-1526
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Canonica G. Walter,Bourdin Arnaud,Peters Anju T.,Desrosiers Martin,Bachert Claus,Weidinger Stephan,Simpson Eric L.,Daizadeh Nadia,Chen Zhen,Kamat Siddhesh,Khan Asif H.,Chao Jingdong,Graham Neil M.H.,Laws Elizabeth,Rossi Ana B.,Ardeleanu Marius,Mannent Leda P.,Amin Nikhil,Ortiz Benjamin,Deniz Yamo,Djandji Michel,Rowe Paul J.

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference39 articles.

1. Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD;Cazzola;Pulm Pharmacol Ther,2015

2. New targets for rapid antidepressant action;Machado-Vieira;Prog Neurobiol,2017

3. Onset of action of biologics in patients with moderate-to-severe psoriasis;Papp;J Drugs Dermatol,2017

4. Asthma management among allergists in Italy: results from a survey;Magnoni;Clin Mol Allergy,2017

5. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes;Macdonald;Proc Natl Acad Sci U S A,2014

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of different biologics for treating chronic rhinosinusitis with nasal polyps: a network meta-analysis;European Archives of Oto-Rhino-Laryngology;2024-08-26

2. Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP;Journal of Allergy and Clinical Immunology;2024-08

3. Use of Dupilumab in Pediatric Patients: A Review;Current Pediatrics Reports;2024-06-20

4. Type-2 severe asthma comorbidities in the era of biologics: time to rethink clinical response?;Expert Review of Respiratory Medicine;2024-05-03

5. IL‐4/IL‐13 pathway in nasal type 2 inflammation: The central role and targeted therapy;Eye & ENT Research;2024-01-12